tiprankstipranks
Trending News
More News >
Astellas Pharma Inc (JP:4503)
:4503
Advertisement

Astellas Pharma (4503) Stock Statistics & Valuation Metrics

Compare
3 Followers

Total Valuation

Astellas Pharma has a market cap or net worth of $2.68T. The enterprise value is ¥3.30T.
Market Cap$2.68T
Enterprise Value¥3.30T

Share Statistics

Astellas Pharma has 1,809,663,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,809,663,100
Owned by Insiders
Owned by Institutions

Financial Efficiency

Astellas Pharma’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 16.27%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)16.27%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee129.61M
Profits Per Employee3.44M
Employee Count14,754
Asset Turnover0.57
Inventory Turnover1.63

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio52.5
PS Ratio0.00
PB Ratio1.76
Price to Fair Value1.71
Price to FCF16.48
Price to Operating Cash Flow13.42
PEG Ratio0.28

Income Statement

In the last 12 months, Astellas Pharma had revenue of 1.91T and earned 50.75B in profits. Earnings per share was 28.35.
Revenue1.91T
Gross Profit1.43T
Operating Income255.67B
Pretax Income31.50B
Net Income50.75B
EBITDA248.30B
Earnings Per Share (EPS)28.35

Cash Flow

In the last 12 months, operating cash flow was 182.81B and capital expenditures -77.97B, giving a free cash flow of 104.85B billion.
Operating Cash Flow182.81B
Free Cash Flow104.85B
Free Cash Flow per Share57.94

Dividends & Yields

Astellas Pharma pays an annual dividend of ¥39, resulting in a dividend yield of 4.97%
Dividend Per Share¥39
Dividend Yield4.97%
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.49
52-Week Price Change-7.60%
50-Day Moving Average1.40K
200-Day Moving Average1.48K
Relative Strength Index (RSI)66.76
Average Volume (3m)5.91M

Important Dates

Astellas Pharma upcoming earnings date is Jul 30, 2025, TBA (Confirmed).
Last Earnings DateApr 25, 2025
Next Earnings DateJul 30, 2025
Ex-Dividend DateSep 29, 2025

Financial Position

Astellas Pharma as a current ratio of 1.13, with Debt / Equity ratio of 54.94%
Current Ratio1.13
Quick Ratio0.85
Debt to Market Cap0.32
Net Debt to EBITDA2.59
Interest Coverage Ratio14.46

Taxes

In the past 12 months, Astellas Pharma has paid -19.51B in taxes.
Income Tax-19.51B
Effective Tax Rate-0.62

Enterprise Valuation

Astellas Pharma EV to EBITDA ratio is 13.02, with an EV/FCF ratio of 19.64.
EV to Sales1.69
EV to EBITDA13.02
EV to Free Cash Flow19.64
EV to Operating Cash Flow16.03

Balance Sheet

Astellas Pharma has $188.37B in cash and marketable securities with ¥831.43B in debt, giving a net cash position of $643.05B billion.
Cash & Marketable Securities$188.37B
Total Debt¥831.43B
Net Cash$643.05B
Net Cash Per Share$355.34
Tangible Book Value Per Share-$14.34

Margins

Gross margin is 78.25%, with operating margin of 13.37%, and net profit margin of 2.65%.
Gross Margin78.25%
Operating Margin13.37%
Pretax Margin1.65%
Net Profit Margin2.65%
EBITDA Margin12.98%
EBIT Margin2.57%

Analyst Forecast

The average price target for Astellas Pharma is $1,749.60, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$1,749.60
Price Target Upside17.46% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast19.25%
EPS Growth Forecast294.48%

Scores

Smart ScoreN/A
AI Score72
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis